摘要
目的评估安罗替尼三线治疗晚期转移性非小细胞肺癌(NSCLC)病人的临床疗效及安全性。方法收集2018年1月至2019年6月在商丘市第三人民医院收治的接受安罗替尼治疗的晚期转移性NSCLC病人37例。收集病人临床资料和服药期间主要不良反应。比较治疗前后外周血中癌胚抗原(CEA)水平和Karnofsky功能状态(KPS)评分,分析安罗替尼的近期疗效与病人一般临床资料的相关性。结果安罗替尼治疗2个疗程后客观有效率(ORR)为40.5%,疾病控制率(DCR)为75.7%;治疗后血清CEA水平为(12.6±3.5)ng/mL低于治疗前(17.9±4.2)ng/mL,治疗后病人的KPS评分(76.8±11.4)分高于治疗前(71.5±10.7)分;病人治疗期间,主要不良反应有中性粒细胞减少(32.4%)和血小板减少(21.6%);临床分期Ⅲb期DCR病人占90.0%,显著高于临床分期Ⅳ期58.8%。驱动基因阳性DCR病人占95.0%,高于驱动基因阴性52.9%。结论安罗替尼三线治疗晚期转移性NSCLC可降低CEA水平,DCR较高,Ⅲ~Ⅳ级的不良反应较少,值得在临床上推广。
Objective To evaluate the clinical efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer.Methods Thirty-seven patients with advanced metastatic NSCLC who were treated with anlotinib in the Third People's Hospital of Shangqiu from January 2018 to June 2019 were collected.The clinical data and main adverse reactions during medication of patients were collected.The carcinoembryonic antigen(CEA)level and Karnofsky functional status(KPS)score in peripheral blood were com‐pared before and after treatment,and the correlation between the short-term efficacy of anlotinib and the general clinical data of pa‐tients was analyzed.Results After 2 courses of anlotinib treatment,the objective response rate(ORR)was 40.5%and the disease con‐trol rate(DCR)was 75.7%.Serum CEA level after treatment was(12.6±3.5)ng/mL lower than before treatment(17.9±4.2)ng/mL.The KPS score of patients after treatment(76.8±11.4)was higher than that before treatment(71.5±10.7).During treatment,the main adverse reactions were neutropenia(32.4%)and thrombocytopenia(21.6%),respectively.The clinical stageⅢb DCR patients accounted for 90.0%,which was significantly higher than the clinical stageⅣstage(58.8%).Driver gene-positive DCR patients accounted for 95.0%,which was significantly higher than driver gene-negative(52.9%).Conclusion Anlotinib multiline treatment for patients with advanced non-small cell lung cancer can reduce CEA levels,DCR is higher and adverse reactions of gradeⅢ-Ⅳare less.It is worthy of clinical promotion.
作者
贾新立
郭银谋
何世威
田秀岭
JIA Xinli;GUO Yinmou;HE Shiwei;TIAN Xiuling(Department of Oncology,Third People's Hospital of Shangqiu,Shangqiu,Henan 476000,China;Department of Oncology,First People's Hospital of Shangqiu,Shangqiu,Henan 476000,China)
出处
《安徽医药》
CAS
2021年第11期2309-2312,共4页
Anhui Medical and Pharmaceutical Journal
关键词
癌
非小细胞肺
安罗替尼
临床疗效
不良反应
Carcinoma,non-small-cell lung
Anlotinib
Clinical efficacy
Adverse reactions
